- Home
- GXAI vs CNSP Comparison
GXAI vs CNSP Comparison
Compare GXAI & CNSP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | GXAI | CNSP |
|---|---|---|
| Founded | 2021 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 8.8M | 3.8M |
| IPO Year | 2023 | 2019 |
Fundamental Metrics
Financial Performance| Metric | GXAI | CNSP |
|---|---|---|
| Price | $1.03 | $6.06 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $20.00 |
| AVG Volume (30 Days) | ★ 76.1K | 17.7K |
| Earning Date | 11-13-2025 | 11-17-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $694,278.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 23205.74 | N/A |
| 52 Week Low | $1.00 | $4.93 |
| 52 Week High | $3.77 | $114.00 |
Technical Indicators
Market Signals| Indicator | GXAI | CNSP |
|---|---|---|
| Relative Strength Index (RSI) | 32.28 | 37.29 |
| Support Level | $1.05 | $6.00 |
| Resistance Level | $1.12 | $7.78 |
| Average True Range (ATR) | 0.06 | 0.60 |
| MACD | 0.00 | -0.09 |
| Stochastic Oscillator | 3.74 | 6.39 |
Price Performance
Historical ComparisonAbout GXAI Gaxos.ai Inc.
Gaxos.AI Inc is revolutionizing the way humans interact with artificial intelligence. The company offers applications related to mental and physical well-being, coaching, and gaming. The group is committed to tackling contemporary challenges such as how to live healthier and how to live longer. In addition to offering human-centered solutions, the company uses empathetic and AI technologies.
About CNSP CNS Pharmaceuticals Inc.
CNS Pharmaceuticals Inc is a clinical-stage pharmaceutical company focused on the development of anticancer drug candidates for the treatment of primary and metastatic brain and central nervous system tumors. It is involved in the development of Berubicin, which is a therapy for the treatment of glioblastoma. Glioblastomas are tumors that arise from astrocytes, which are star-shaped cells that make up the supportive tissue of the brain.